联合检测p53自身抗体与EB病毒VCA-IgA对鼻咽癌的诊断价值

doi:10.3969/j.issn.1004-616x.2015.01.006

癌变·畸变·突变

联合检测p53自身抗体与EB病毒VCA-IgA对鼻咽癌的诊断价值

彭裕辉¹，谢长乐²，庄珊珊¹，张利群³，许镒洧^1，*

汕头大学医学院附属肿瘤医院检验科，广东汕头 515041

收稿日期:2014-10-11 修回日期:2014-12-07 出版日期:2015-01-31 发布日期:2015-01-31
通讯作者: 许镒洧， E-mail：yiwei512@126.com
作者简介:彭裕辉，E-mail：pengyuhui666@163.com
基金资助:
广东省科技计划项目(2013B021800250)；汕头市医疗科技计划项目(汕府科[2013]88号)

Combined analysis of autoantibodies against p53 and Epstein-Barr virus VCA-IgA for improved diagnosis of nasopharyngeal carcinoma

PENG Yuhui¹，XIE Changle²，ZHUANG Shanshan¹，ZHANG Liqun³，XU Yiwei^1，*

Department of Clinical Laboratory, Tumor Hospital of Shantou University Medical College, Shantou 515041

Received:2014-10-11 Revised:2014-12-07 Online:2015-01-31 Published:2015-01-31

摘要/Abstract

摘要：

目的：探讨联合检测p53自身抗体与EB病毒VCA-IgA在鼻咽癌患者中的诊断意义。方法：采用酶联免疫吸附实验(ELISA)检测242例鼻咽癌患者和218 例正常对照者血清中p53自身抗体和EB病毒壳抗体(VCA-IgA)的表达水平。结果：血清p53自身抗体的水平在鼻咽癌患者组明显高于正常对照组，差异有统计学意义(P<0.01)。p53自身抗体和VCA-IgA对鼻咽癌的诊断敏感度分别为40.1% (95%CI：33.9%~46.6%) 和47.5%(95%CI：41.1%~54.0%)；特异度分别为95.0%(95%CI：90.9%~97.3%)和95.4% (95%CI： 91.5%~97.7%)，两者联合检测的敏感度和特异度分别为69.4%(95%CI：63.1%~75.0%)和90.8%(95%CI：86.0%~94.2%)。p53自身抗体、VCA-IgA和两者联合检测在早期鼻咽癌患者中的阳性表达均明显高于正常对照组(P均<0.01)。p53自身抗体的阳性表达率与鼻咽癌患者的性别、年龄、T分期、N分期和总TNM分期之间均无明显相关性(P>0.05)。结论：血清p53自身抗体作为一种潜在的诊断标志物，与VCA-IgA联合检测可能有助于筛查和诊断鼻咽癌。

关键词: p53, 自身抗体, EB病毒, VCA-IgA, 鼻咽癌, 诊断

Abstract:

OBJECTIVE: To evaluate the diagnostic value of serum autoantibodies against p53 in patients with nasopharyngeal carcinoma. METHODS：The study included 242 patients with NPC and 218 normal controls. Serum levels of autoantibodies against p53 and classical Epstein-Barr virus VCA-IgA were measured by Enzyme-linked immunosorbent assay (ELISA). RESULTS：Serum levels of autoantibodies against p53 were significantly higher in NPC than in normal controls (P<0.01). Measurement of autoantibodies against p53 and VCA-IgA demonstrated a sensitivity/specificity of 40.1% (95%CI：33.9%-46.6%)/95.0% (95%CI：90.9%-97.3%) and 47.5% (95%CI：41.1%-54.0%)/95.4% (95%CI：91.5%-97.7%)，respectively. The combination of autoantibodies against p53 and VCA-IgA yielded an enhanced sensitivity of 69.4% (95%CI：63.1%-75.0%) and a similar specificity of 90.8% (95%CI：86.0%-94.2%). Moreover，detection of autoantibodies against p53 could differentiate early stage NPC patients from normal controls. The positive rate of autoantibodies against p53 was not significantly related to age，gender，T stage，N stage or overall stage (P>0.05). CONCLUSION：Autoantibodies against p53 might be used as a potential biomarker supplementary to VCA-IgA for screening and diagnosis of NPC.

Key words: p53, autoantibody, Epstein-Barr virus, VCA-IgA, nasopharyngeal carcinoma, diagnosis

彭裕辉，谢长乐，庄珊珊，张利群，许镒洧. 联合检测p53自身抗体与EB病毒VCA-IgA对鼻咽癌的诊断价值[J]. 癌变·畸变·突变, doi: 10.3969/j.issn.1004-616x.2015.01.006.

PENG Yuhui，XIE Changle，ZHUANG Shanshan，ZHANG Liqun，XU Yiwei. Combined analysis of autoantibodies against p53 and Epstein-Barr virus VCA-IgA for improved diagnosis of nasopharyngeal carcinoma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, doi: 10.3969/j.issn.1004-616x.2015.01.006.

参考文献

[1] Razak AR，Siu LL，Liu FF，et al. Nasopharyngeal carcinoma：the next challenges[J]. Eur J Cancer，2010， 46(11)：1967-1978.

[2] 曹新平，卢泰祥，叶伟军，等. Ⅰ、Ⅱ期鼻咽癌外照射加腔内放疗远期疗效的前瞻性研究[J]. 癌症，2007，26(2)：204-207.

[3] Chen Y，Sun Y，Liang SB，et al. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China[J]. Cancer，2013，119(12)：2230-2238.

[4] Chan KH，Gu YL，Ng F，et al. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma[J]. Int J Cancer，2003，105(5)：706-709.

[5] Soussi T. p53 Antibodies in the sera of patients with various types of cancer：a review[J]. Cancer Res，2000，60(7)： 1777-1788.

[6] Chen L，Mao YP，Xie FY，et al. The seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China[J]. Radiother Oncol，2012，104(3)：331-337.

[7] Crawford LV，Pim DC，Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer[J]. Int J Cancer，1982，30(4)：403-408.

[8] Xu YW，Peng YH，Chen B，et al. Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma[J]. Am J Gastroenterol，2014，109(1)：36-45.

[9] Zhang J，Xu Z，Yu L，et al. Assessment of the potential diagnostic value of serum p53 antibody for cancer：a meta-analysis[J]. PLoS One，2014，9(6)：e99255.

[10] Roth J，Dittmer D，Rea D，et al. p53 as a target for cancer vaccines：recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge[J]. Proc Natl Acad Sci U S A，1996，93(10)：4781-4786.

[11] Yamamoto S，Chishima T，Adachi S，et al. Serum p53 antibody in breast cancer[J]. Cancer Biomark，2014，14(4)： 203-206.

[12] Pedersen JW，Gentry-Maharaj A，Fourkala EO，et al. Early detection of cancer in the general population：a blinded case-control study of p53 autoantibodies in colorectal cancer[J]. Br J Cancer，2013，108(1)：107-114.

[13] Chang KP，Hao SP，Chang JH，et al. Macrophage inflammatory protein-3alpha is a novel serum marker for nasopharyngeal carcinoma detection and prediction of treatment outcomes[J]. Clin Cancer Res，2008，14(21)：6979-6987.

[14] Liu Y，Fang Z，Liu L，et al. Detection of Epstein-Barr virus DNA in serum or plasma for nasopharyngeal cancer：a meta-analysis[J]. Genet Test Mol Biomarkers，2011，15(7/8)：495-502.

[1]	郭照萌, 张华, 张鹏. Orai1对鼻咽癌细胞侵袭和上皮-间充质转化的影响及其机制[J]. 癌变·畸变·突变, 2021, 33(6): 420-425.
[2]	黄晓华, 牛永东, 石刚刚. 核受体FXR激活对宫颈癌CaSki细胞增殖的抑制效应及其作用机制[J]. 癌变·畸变·突变, 2021, 33(4): 302-306.
[3]	刘春燕, 张爱华. p53的翻译后修饰及其与砷中毒致人体多器官损伤关系的研究进展[J]. 癌变·畸变·突变, 2021, 33(2): 157-160.
[4]	王耀坤, 陈珏晓, 张明远, 邵长利, 杨玉, 商宇. 基于数据库的未分化甲状腺癌基因组变异分析及靶向药物筛选[J]. 癌变·畸变·突变, 2021, 33(1): 53-57.
[5]	赵子慧, 王绪华. 非小细胞肺癌伴随诊断的研究进展[J]. 癌变·畸变·突变, 2021, 33(1): 66-71,76.
[6]	黎梓蕊, 许键, 李红文, 张鹏. 口腔癌相关microRNA的研究进展[J]. 癌变·畸变·突变, 2020, 32(6): 481-484.
[7]	陶燕, 李兰兰, 卢建中, 刘善辉, 付生军, 张静. 基于生物信息学数据库探讨FOXO3基因在膀胱癌中的表达及临床意义[J]. 癌变·畸变·突变, 2020, 32(5): 374-379.
[8]	徐海明, 刘科良, 郝艳星, 汪岭, 刘志宏, 德小明. 生物标志物的联合检测对矽肺早期辅助诊断的价值[J]. 癌变·畸变·突变, 2020, 32(5): 395-397,401.
[9]	尹璐, 马成斌, 刘平, 张祎, 赵学军. P16/Ki-67双染联合DNA倍体分析在ASCUS分流诊断中的应用价值[J]. 癌变·畸变·突变, 2020, 32(4): 264-268.
[10]	陈琪, 钟茜, 岳文涛. RNA结合基元蛋白24通过调控HOTAIR表达抑制鼻咽癌细胞增殖[J]. 癌变·畸变·突变, 2020, 32(4): 275-280.
[11]	陈秀琼, 孟凡桥, 熊华, 王雅丽, 周洋媚, 唐雯华, 邹燕梅. 胃癌相关核心基因的生物信息学分析[J]. 癌变·畸变·突变, 2019, 31(4): 308-314.
[12]	鲍清, 王康. 伴CIC-DUX4融合基因的高级别未分化圆细胞肉瘤的研究进展[J]. 癌变·畸变·突变, 2019, 31(2): 157-161,165.
[13]	丁文评, 陆元元, 童文侠, 周蔼斌, 孔祥, 陈意红. 氯喹通过激活P38MAPK通路诱导人肝癌HepG2细胞凋亡[J]. 癌变·畸变·突变, 2018, 30(6): 430-434.
[14]	姜朋涛, 胡志芳, 高兴春, 郭娜, 张典, 姜凤良. p53在调控DNA损伤所致MDAMB-231细胞死亡中的作用及其机制[J]. 癌变·畸变·突变, 2018, 30(5): 349-353.
[15]	贺荟静, 刘金成, 刘芡芡, 王云. 变异型EBER2通过抑制PKR通路增强鼻咽癌细胞抗凋亡能力[J]. 癌变·畸变·突变, 2018, 30(5): 333-338,344.

联合检测p53自身抗体与EB病毒VCA-IgA对鼻咽癌的诊断价值

Combined analysis of autoantibodies against p53 and Epstein-Barr virus VCA-IgA for improved diagnosis of nasopharyngeal carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价